Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties-Reference-Cited by-同舟云学术

Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties

Published:2016-02-05 Issue:6 Volume:59 Page:2497-2511
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Johansson Anders¹,Löfberg Christian¹,Antonsson Madeleine¹,von Unge Sverker¹,Hayes Martin A.¹,Judkins Robert¹,Ploj Karolina¹,Benthem Lambertus¹,Lindén Daniel¹,Brodin Peter¹,Wennerberg Marie¹,Fredenwall Marléne¹,Li Lanna¹,Persson Joachim¹,Bergman Rolf¹,Pettersen Anna¹,Gennemark Peter¹,Hogner Anders¹

Affiliation:

1. Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg, 431 83 Mölndal, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01654

Reference59 articles.

1. Food and Drug Administration's Obesity Drug Guidance Document

2. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

3. Global obesity: trends, risk factors and policy implications